JGC
PTCT icon

J. Goldman & Co’s PTC Therapeutics PTCT Stock Holding History

J. Goldman & Co’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,816
Closed -$480K – 697
2025
Q3 		$480K Sell
7,816
-36,242
-82% -$1.89M 0.01% 384
2025
Q2 		$2.15M Buy
+44,058
New +$2.09M 0.05% 268
2018
Q1 		– Sell
-653,284
Closed -$10.9M – 417
2017
Q4 		$10.9M Buy
653,284
+625,104
+2,218% +$10.6M 0.57% 52
2017
Q3 		$564K Buy
28,180
+13,500
+92% +$264K 0.03% 267
2017
Q2 		$269K Sell
14,680
-1,247,042
-99% -$16.8M 0.01% 265
2017
Q1 		$12.4M Buy
1,261,722
+1,191,772
+1,704% +$14.4M 0.61% 40
2016
Q4 		$763K Buy
+69,950
New +$734K 0.05% 233
2015
Q2 		– Sell
-10,466
Closed -$637K – 302
2015
Q1 		$637K Buy
+10,466
New +$639K 0.04% 239

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

J. Goldman & Co's PTCT Position: Q4 2025 in Review

J. Goldman & Co sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 7,816 shares — an estimated $480K sold.

J. Goldman & Co first reported a position in PTCT in Q1 2015 and held it in 8 quarters. The position peaked at $12.4M in Q1 2017. 351 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

  • J. Goldman & Co reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 7,816 PTC Therapeutics shares in Q4 2025, an estimated $480K.
  • J. Goldman & Co first reported a position in PTC Therapeutics in Q1 2015 and held it in 8 quarters.
  • J. Goldman & Co's PTC Therapeutics position peaked at $12.4M in Q1 2017.
  • 351 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.